Aprea Therapeutics (APRE) Cash from Investing Activities (2018 - 2024)
Aprea Therapeutics (APRE) posted quarterly Cash from Investing Activities of -$7500.0 for Q2 2024, up 5.99% quarter-over-quarter from -$7978.0 in Q1 2024.
Aprea Therapeutics (APRE) Cash from Investing Activities (2018 - 2024) Analysis & Trends
Aprea Therapeutics (APRE) has reported Cash from Investing Activities for 5 consecutive years, with -$7500.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Cash from Investing Activities changed N/A year-over-year to -$7500.0; the TTM figure through Dec 2024 stood at -$15478.0 (up 25.21% YoY), while the FY2024 annual figure was -$15478.0, up 83.37% from the prior year.
- Cash from Investing Activities improved to -$7500.0 in Q2 2024 per APRE's latest filing, from -$7978.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $2021.0 in Q2 2020 and bottomed at -$16290.0 in Q4 2020.
- Historically, Cash from Investing Activities has averaged -$6905.3 across 3 years, with a median of -$7500.0 in 2024.
- On a YoY basis, Cash from Investing Activities climbed as much as 107.08% in 2020 and fell as far as 12.61% in 2020.
- Aprea Therapeutics' Cash from Investing Activities stood at -$16290.0 in 2020, then jumped by 56.11% to -$7150.0 in 2023, then decreased by 4.9% to -$7500.0 in 2024.
- Business Quant data shows APRE's Cash from Investing Activities at -$7500.0 in Q2 2024, -$7978.0 in Q1 2024, and -$7150.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7,500.00 |
| Jun 30, 2024 | -7,500.00 |
| Mar 31, 2024 | -7,978.00 |
| Mar 31, 2024 | -7,978.00 |
| Dec 31, 2023 | -7,150.00 |
| Dec 31, 2023 | -7,150.00 |
| Dec 31, 2020 | -16,290.00 |
| Dec 31, 2020 | -16,290.00 |
| Sep 30, 2020 | 725.00 |
| Sep 30, 2020 | 725.00 |
| Jun 30, 2020 | 2,021.00 |
| Jun 30, 2020 | 2,021.00 |
| Mar 31, 2020 | -12,165.00 |
| Mar 31, 2020 | -12,165.00 |
| Dec 31, 2019 | -14,466.00 |
| Dec 31, 2019 | -14,466.00 |
| Sep 30, 2019 | -10,246.00 |
| Sep 30, 2019 | -10,246.00 |
| Dec 31, 2018 | 804.00 |
| Dec 31, 2018 | 804.00 |